3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
9
Terminated
2
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
7
Leukemia, Myeloid, Acute
6
Breast Neoplasms
6
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Skin Neoplasms
3
Mesothelioma, Malignant
3
Lymphoma, Non-Hodgkin
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Sarcoma
2
Recurrence
2
Rectal Neoplasms
2
Pleural Effusion, Malignant
2
Neuroblastoma
2
Neoplasms
2
Multiple Myeloma
2
Lung Neoplasms
2
Leukemia, Myeloid
2
Leukemia
2
Head and Neck Neoplasms
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Merkel Cell
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Interventions
Cyclophosphamide
27
fludarabine
18
Rituximab
17
obinutuzumab
11
venetoclax
9
Bendamustine Hydrochloride
9
Lenalidomide
8
zanubrutinib
6
Prednisone
6
Doxorubicin
6
Blood Specimen Collection
6
pembrolizumab
5
fludarabine phosphate
5
Biopsy
5
ibrutinib
4
glofitamab
4
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Exercise
4
loncastuximab tesirine
3
gamma-Globulins
3
axicabtagene ciloleucel
3
acalabrutinib
3
Temozolomide
3
Surveys and Questionnaires
3
Palliative Care
3
Mycophenolic Acid
3
Methotrexate
3
Mesna
3
Magnetic Resonance Spectroscopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma
×
Interleukin-2
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled